Hypertension Outcomes of Adrenalectomy for Unilateral Primary Aldosteronism
Abstract Purpose: To evaluate laboratory and clinical results after unilateral adrenalectomy in patients with primary aldosteronism (PHA).Methods: A cross-sectional analysis was performed using data from patients who underwent transperitoneal laparoscopic adrenalectomy for PHA, between January 2008 and December 2019. Surgical indications were based on adrenal venous sampling without ACTH stimulation. Analyses included patient demographics; preoperative clinical, pharmacological, laboratory, and radiological data; and postoperative results assessed after a median of 4 months. Antihypertensive drug use was quantified by estimating the daily defined dose (DDD) of antihypertensive medication, thus enabling standardised comparison of dosage between the drug classes. Statistical assessments included univariable and multivariable logistic regression analysis. Results: This study enrolled 87 patients. The patients were taking 5.4 DDD of antihypertensive medication before surgery, and 3.0 DDD after surgery. In 45 cases (52%), the aldosterone-to-renin ratio normalized after surgery (“laboratory cured”), while 21 patients (24%) required no antihypertensive drugs after surgery (“clinically cured”). Among the 66 patients who were not clinically cured, 51 (77%) had a reduction of their DDD. Thus, surgery had a positive effect on hypertension control in 72 cases (83% of all enrolled patients). Multivariable logistic regression showed that clinical cure of hypertension was independently associated with female gender, absence of diabetes mellitus, and DDD < 4.Conclusion: A majority of patients undergoing unilateral adrenalectomy for PHA achieved markedly improved hypertension control, despite almost halving their antihypertensive medication. About a quarter of patients were cured and able to cease using all antihypertensive drugs.